{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:34:30Z","timestamp":1789389270888,"version":"build-2803163510"},"reference-count":13,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cytarabine is one of the main chemotherapy drugs used to treat hematological malignancies. Neurotoxicity is an increasingly recognized adverse effect of high-dose cytarabine therapy and occurs in 10% to 25% of patients. There is very little experience with cytarabine retreatment following neurotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report a case of a man who was diagnosed with chemotherapy-induced cerebellar syndrome. He was treated with high doses of cytarabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The patient was successfully retreated at full dose after experiencing cytarabine-induced cerebellar toxicity during the first cycle of a chemotherapy regimen. He did not develop any neurological complications and successfully underwent hematopoietic stem cell transplantation. He is currently in complete remission and free of disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This original case report assesses the possibility of retreatment without the need for dose reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552221076777","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T07:53:25Z","timestamp":1643702005000},"page":"1634-1636","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Retreatment with full-dose cytarabine in a patient with previous neurological toxicity"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-3588","authenticated-orcid":false,"given":"N\u00faria Meca","family":"Casasnovas","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hospital M\u00fatua Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Manzaneque","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital M\u00fatua Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Munta\u00f1ola","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospital M\u00fatua Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-4490","authenticated-orcid":false,"given":"Gen\u00eds","family":"Castells","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital M\u00fatua Terrassa, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"key":"bibr1-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.04.013"},{"key":"bibr2-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219898747"},{"key":"bibr3-10781552221076777","first-page":"142","volume":"8","author":"Varghese DR","year":"2018","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"bibr4-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02771.x"},{"key":"bibr5-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2014.12.017"},{"key":"bibr6-10781552221076777","first-page":"338","volume":"54","author":"Olavarria E","journal-title":"Am J Hematol"},{"key":"bibr7-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689281"},{"key":"bibr8-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0171-7"},{"key":"bibr9-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1563"},{"key":"bibr10-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.6.927"},{"key":"bibr11-10781552221076777","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.6.948"},{"key":"bibr12-10781552221076777","unstructured":"Autologous conditioning protocol BEAM (carmustine, etoposide, cytarabine, melphalan. EVIQ: https:\/\/www.eviq.org.au\/haematology-and-bmt\/blood-and-marrow-transplant\/autologous\/405-autologous-conditioning-protocol-beam-carmust"},{"key":"bibr13-10781552221076777","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00004"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221076777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552221076777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552221076777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:26:30Z","timestamp":1777688790000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552221076777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552221076777"],"URL":"https:\/\/doi.org\/10.1177\/10781552221076777","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}